1-(2-(4-溴苯氧基)乙基)哌啶 | 836-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(2-(4-溴苯氧基)乙基)哌啶
• 英文名称: 1-[2-(4-bromophenoxy)ethyl]piperidine
• 英文别名: 4-(2-(N-piperidinyl)ethoxy)-1-bromobenzene；1-bromo-4-(2-N-piperidinyl-ethoxy)benzene；4-[2-(1-piperidino)ethoxy]phenyl bromide；1-(2-(4-bromophenoxy)ethyl)piperidine；1-bromo-4-(2-piperidinoethoxy)benzene；1-[2-(4-bromo-phenoxy)-ethyl]-piperidine
• CAS: 836-58-8
• 化学式: C₁₃H₁₈BrNO
• mdl: MFCD01308459
• 分子量: 284.196
• InChiKey: PDUKJODPFIFHNK-UHFFFAOYSA-N

物化性质

• 沸点：
  127-133 °C(Press: 1.5 Torr)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-(2-(4-溴苯氧基)乙基)哌啶 在 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 (4-(2-(piperidin-1-yl)ethoxy)phenyl)boronic acid
  参考文献：
  名称：

  Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer’s Disease: Design, Synthesis, and Characterization of Pyrazines

  摘要：

  Glycogen synthase kinase-3 beta, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism. Active forms of GSK3 beta localize to pretangle pathology including dystrophic neuritis and neurofibrillary tangles in Alzheimer's disease (AD) brain. By using a high throughput screening (HTS) approach to search for new chemical series and cocrystallization of key analogues to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and blood-brain barrier penetrance. The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.

  DOI：

  10.1021/jm201724m
• 作为产物：
  描述：

  4-溴苯酚 、 1-(2-氯乙基)哌啶盐酸盐 在 苄基三乙基氯化铵 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以98.2%的产率得到1-(2-(4-溴苯氧基)乙基)哌啶
  参考文献：
  名称：

  17α-甲基-11β-芳基雌二醇的合成：铈（III）介导的酮烷基化的大规模应用

  摘要：

  17α-Methyl-11β-arylestradiol (17α-methyl-11β-(4-(2-(1-piperidinyl)ethoxy)phenyl)estra-1,3,5(10)-triene-3,17β-diol) 是一种Aventis Pharma 开发的用于治疗骨质疏松症的新分子。它是由去甲甾体中间体亚乙基萜酮（3,3-ethylenedioxyestra-5(10)-9(11​​)-diene-17-one）在中试工厂规模生产的。5(10)-烯烃的立体选择性环氧化是通过过氧化氢和六氯丙酮进行的，这是测试系统中选择性最高的。11β-芳基附属物作为由相关格氏试剂催化生成的铜酸盐引入。A-环被乙酰溴和乙酸酐的混合物芳构化。该反应通过在自动化工作站上进行的实验设计进行了优化。讨论了这种方法的优点和局限性。最后一步由甲基溴化镁和脱水三氯化铈对 17-酮的立体有择烷基化组成。药物物质结晶为水合物（过

  DOI：

  10.1021/op010051w

文献信息

• Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
  申请人：——

  公开号：US20040259915A1

  公开（公告）日：2004-12-23

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新颖的含杂原子四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用，以及它们的制备方法。本发明的化合物在治疗和/或预防与雌激素耗竭相关的疾病中具有用途，例如热潮红、阴道干燥、骨量减少和骨质疏松症；激素敏感性癌症以及乳腺、子宫内膜、宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎，以及作为避孕剂，单独使用或与孕激素或孕激素拮抗剂联合使用。
• Controlled Single and Double Iodofluorination of Alkynes with DIH- and HF-Based Reagents
  作者：Lukas Pfeifer、Véronique Gouverneur

  DOI：10.1021/acs.orglett.8b00321

  日期：2018.3.16

  terminal alkynes using 1,3-diiodo-5,5,-dimethylhydantoin and HF-based reagents is disclosed. This approach is used to prepare a fluorinated tamoxifen derivative in two steps from commercially available starting materials. A facile method enabling controlled regioselective double iodofluorination of terminal alkynes is also presented.

  公开了使用1，3-二碘-5，5，-二甲基乙内酰脲和基于HF的试剂进行内部和末端炔的区域和立体选择性碘氟化的新方案。该方法用于从市售原料中分两步制备氟化他莫昔芬衍生物。还提出了一种可控制末端炔烃的区域选择性双碘氟化的简便方法。
• Novel Compounds
  申请人：——

  公开号：US20020107252A1

  公开（公告）日：2002-08-08

  The invention relates to heteroaromatic carboxamides of formula (I), 1 wherein A, R 1 , R 2 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  这项发明涉及到式(I)的杂环芳香族羧酰胺， 其中A、R1、R2和X如规范中定义，以及用于它们制备的过程和中间体，含有它们的药物组合物以及它们在治疗中的应用。
• Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors
  作者：Jian-kang Jiang、Xiuli Huang、Khalida Shamim、Paresma R. Patel、Arthur Lee、Amy Q. Wang、Kimloan Nguyen、Gregory Tawa、Gregory D. Cuny、Paul B. Yu、Wei Zheng、Xin Xu、Philip Sanderson、Wenwei Huang

  DOI：10.1016/j.bmcl.2018.09.006

  日期：2018.11

  The pyrazolo[1,5-a]pyrimidine LDN-193189 is a potent inhibitor of activin receptor-like kinase 2 (ALK2) but is nonselective for highly homologous ALK3 and shows only modest kinome selectivity. Herein, we describe the discovery of a novel series of potent and selective ALK2 inhibitors by replacing the quinolinyl with a 4-(sulfamoyl)naphthyl, yielding ALK2 inhibitors that exhibit not only excellent discrimination

  吡唑并[1，5 - a ]嘧啶LDN-193189是激活素受体样激酶2（ALK2）的有效抑制剂，但对高度同源的ALK3没有选择性，并且仅显示适度的激酶组选择性。在本文中，我们描述了通过用4-（氨磺酰基）萘基取代喹啉基，产生一系列ALK2抑制剂的新发现，这些ALK2抑制剂不仅显示出对ALK3的出色区分能力，而且还具有较高的动因选择性。另外，优化的化合物23表现出良好的ADME和体内药代动力学特性。
• Intermediates and processes for preparing benzo (b) thiophenes
  申请人：Eli Lilly and Company

  公开号：US06018056A1

  公开（公告）日：2000-01-25

  The instant invention provides processes for preparing compounds of formula IV, V, and IX, having the structures provided hereinbelow: ##STR1## These compounds are useful intermediates in the further preparation of benzo[b] thiophenes.

  本发明提供了制备具有以下结构的化合物IV、V和IX的过程：##STR1## 这些化合物在进一步制备苯并[b]噻吩中起到了重要的中间体作用。